Additional US Patent Granted for VivaGel® BV
Starpharma today announced the granting of a patent by the US Patent Office for VivaGel® related to the prevention of recurrence of bacterial vaginosis (BV). The patent’s term is to 2032 providing an extension of seven years over granted VivaGel® patents. Additional term may also be available subject to timing of regulatory approval.
OTCQX Life Sciences Presentation
Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that as part of its OTCQX investor communications, a pre-recorded presentation by Chief Executive Officer Dr Jackie Fairley will be broadcast at VirtualInvestorConferences.com on Thursday, October 1, 2015 at 12.15pm (EDT time). The presentation is part of a special OTCQX Life Sciences virtual Conference.
The Australian: Starpharma wins EU approval for VivaGel
The Australian reports that "Starpharma has been granted approval to market its VivaGel BV in the European Union's 28 member countries, where more than 260 million women live. The lubricant treats bacterial vaginosis (BV), the most common vaginal infection experienced by women around the world".
EU Marketing Approval Granted for VivaGel® BV
Starpharma today announced it has received, overnight, marketing approval in the European Union (EU) for VivaGel® BV for the treatment and rapid relief of bacterial vaginosis (BV) including symptoms.
The Wall Street Journal/The Australian: Australia looks to health care as a remedy for resource slump doldrums
The Wall Street Journal's Rachel Pannett comments that 'Australia is taking a page from Silicon Valley's playbook as it seeks to reinvigorate its resource-dependent economy at the end of a long commodities boom, placing bets on biotechnology and digital health care'. Tax incentives for R&D have moved Australia to fourth place globally for biotechnology innovation, with a further boost expected following a change of Prime Minister from Tony Abbott to Malcolm Turnbull. Starpharma is featured in the article for its drug delivery technology and recent licensing deal with AstraZeneca.
The Wall Street Journal: 5 Things to know about Australia's biotech push
The Wall Street Journal's Rachell Pannett provides a summary of Australia's biotech industry, highlighting Starpharma's drug delivery technology as one of Australia's 'interesting discoveries'.
ABC's The Business: Interview with Dr Jackie Fairley following AstraZeneca deal
Ticky Fullerton of ABC's The Business interview's Starpharma CEO Dr Jackie Fairley following a 20% share price increase "on the back of a deal signed with American drug giant AstraZeneca. It will use Starpharma's drug delivery nanotechnology to target cancer treatment in the body."
The Australian: Starpharma signs AstraZeneca deal
The Australian's Sarah Jane Tasker reports that "Starpharma has inked a potential billiondollar-plus deal with pharmaceutical giant AstraZeneca for the use of its drug delivery technology. AstraZeneca will use Starpharma's technology to develop and commercialise specific cancer drugs, leaving the rest of the oncology space open for Starpharma to further commercialise DEP with third parties".
The Age and SMH: Starpharma shares soar 21 percent on AstraZeneca deal news
Tim Binstead reports on the deal between Starpharma and AstraZeneca that could be worth more than the $US450 million per drug using Starpharma's drug delivery technology, providing "hard proof" that Starpharma's drug delivery platform could be worth billions.
Starpharma signs drug delivery license with AstraZeneca
Starpharma today announced the signing of a licensing agreement with global pharmaceutical company AstraZeneca. The agreement enables the development and commercialisation by AstraZeneca of compounds directed at a defined family of targets using Starpharma’s DEP® drug delivery technology. The DEP® platform centres on use of Starpharma’s proprietary dendrimers, with the aim of enhancing the dosing and efficacy characteristics of pharmaceuticals.